Claims
- 1. A nanoparticle comprising:
(i) magnetic core having one or more magnetic metal oxide crystals; and (ii) a noncrosslinked polymer coating associated with the core, wherein the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups, wherein a portion of the carboxyl groups are associated with the crystals.
- 2. The nanoparticle of claim 1 wherein reactive primary amino groups are associated with polymer through a peptidyl linkage of the formula:
- 3. The nanoparticle of claim 1, wherein the magnetic core comprises one or more superparamagnetic iron oxide crystals.
- 4. The nanoparticle of claim 3 wherein the superparamagnetic core has a diameter between about 1 nm and about 25 nm.
- 5. The nanoparticle of claim 4 where in the superparamagnetic core has a diameter between about 3 nm and about 10 nm.
- 6. The nanoparticle of claim 5 wherein the core has a diameter about 5 nm.
- 7. The nanoparticle of claim 1 wherein the nanoparticle has diameter between about 15 nm and 100 nm.
- 8. The nanoparticle of claim 7 wherein the nanoparticle has a diameter between about 20 nm and about 100 nm.
- 9. The nanoparticle of claim 1 wherein the coating is selected from the group of polymers consisting of natural polymers, synthetic polymers and derivatives thereof.
- 10. The nanoparticle of claim 1 wherein the polymer is carboxymethyldextran.
- 11. The nanoparticle of claim 1 wherein the nanoparticle is conjugated with a biomolecule.
- 12. The nanoparticle of claim 11 wherein the biomolecule has at least one sulfhydryl group wherein the sulfhydryl group reacts with an amino group on the coating.
- 13. A nanoparticle-bioconjugate molecule comprising:
(i) a nanoparticle, the nanoparticle comprising
(a) a magnetic core having one or more magnetic metal oxide crystals; (b) a noncrosslinked polymer coating associated with the core, wherein the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups, wherein a portion of the carboxyl groups are associated with the crystals; (ii) a biomolecule linked to the nanoparticle, wherein the biomolecule has at least one sufhydryl group linked to the amino group.
- 14. The a nanoparticle-bioconjugate of claim 13 wherein the amino groups are associated with polymer through a peptidyl linkage of the formula:
- 15. A process for synthesizing an amine functionalized magnetic metal oxide nanoparticle comprising:
i. obtaining a polymer having a plurality of carboxyl groups attached thereto, ii. contacting the polymer with magnetic metal oxide to produce a coated magnetic metal oxide wherein a portion of the carboxyl groups are associated with the metal oxide; iii. reacting the coated magnetic metal oxide of step (ii) with a diamine.
- 16. The process of claim 15 wherein the diamine is ethylene diamine.
- 17. The process of claim 15 wherein the diamine is hexane diamine.
- 18. The process of claim 15 wherein step (ii) further comprises the steps of
(a) providing a solution of soluble iron salts; (b) converting the iron salts into iron oxide crystals; and (c) removing unassociated polymer.
- 19. The process of claim 18 wherein the step of converting the iron salts into iron oxides further includes the steps of:
(d) heating the iron salts to a temperature between about 4° C. and about 20° C.; (e) adding an amount of base to raise the pH to about 8 or higher to form iron oxides.
- 20. The process of claim 19 further including the step of heating the iron oxides to a temperature about 60° C. or more for at least 30 minutes.
- 21. A pharmaceutical composition comprising:
(A) A nanoparticle-bioconjugate molecule comprising:
(i) a nanoparticle, the nanoparticle comprising
(a) a magnetic core having one or more magnetic metal oxide crystals; (b) a noncrosslinked polymer coating associated with the core, wherein the polymer coating has a plurality of carboxyl groups and plurality of reactive primary amino groups, wherein a portion of the carboxyl groups are associated with the crystals; (ii) a biomolecule linked to the nanoparticle, wherein the biomolecule has at least one sufhydryl group linked to at least one amino group; and (B) a pharmaceutically acceptable carrier.
RELATED APPLICATIONS
[0001] This Application claims priority under 35 USC 119(e) to provisional patent application U.S. No. 60/345,233 filed Jan. 2, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60345233 |
Jan 2002 |
US |